Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 534-541

  Halina, Antosz ^a   Artur, Paterski ^a   Barbara, Marzec Kotarska ^a   Joanna, Sajewicz ^a   Anna, Dmoszyńska ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

B CLL; c Myc; TP 53

Indexed keywords

CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLIN D2 GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; ONCOGENE C MYC; P21WAF1 GENE; P27KIP1 GENE; PERIPHERAL LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 79958029762     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0048-5     Document Type: Article

References (36)

1. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-764.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
3. Kipps TJ. Chronic lymphocytic leukaemia. Curr Opin Hematol. 2000;7:223-234.
4. Solvason N, Wu WW, Parry D, et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 2000;12:631-638.
5. Katayose Y, Kim M, Rakkar ANS, Li ZW, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 1997;57:5441-5445.
6. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41-47.
7. Ciszak L, Wołowiec D, Kosmaczewska A, Boæko D, Frydecka I. Białko p27: budowa, funkcje biologiczne oraz udział w patomechanizmie procesów rozrostowych. Post Biol Kom. 2000;27:481-503.
8. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2:764-776.
9. Pajic A, Spitkovsky D, Christoph B, et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000;87:787-793.
10. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AMR, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
11. Sanhes L, Tang R, Delmer A, DeCaprio JA, Ajchenbaum- Cymbalista F. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia. 2003;17:1104-1111.
12. Wang XT, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 1997;15:2991-2998.
13. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
14. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
15. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 2002;99:4554-4561.
16. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342-4349.
17. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmunity Rev. 2007;7:127-131.
18. Kienle DL, Korz C, Hosch B, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol. 2005;23:3780-3792.
19. Koníková E, Kusenda J. Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma. 2003;50:31-40.
20. Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol. 2003;31:218-225.
21. Gottifredi V, McKinney K, Poyurovsky MV, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem. 2004;279:5802-5810.
22. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum- Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood. 1998;91:4694-4700.
23. Ricciardi MR, Petrucci MT, Gregorj C, et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol. 2001;113:391-399.
24. Werner CA, Döhner H, Joos S, et al. High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. Am J Pathol. 1997;151:335-342.
25. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 2002;16:327-334.
26. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782-792.
27. Sher CJ. G1 phase progression: cycling on cue. Cell. 2007; 79:551-555.
28. Hamblin TJ. ZAP-70 levels do change in CLL but not very often. Leuk Lymphoma. 2007;8:1059-1060.
29. Paul JT, Henson ES, Mai S, et al. Cyclin D expression in chronic lymphocytic leukemia. Leuk Lymphoma. 2005;46: 1275-1285.
30. Grdisa M. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins. Croat Med J. 2004;45:136-141.
31. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A. 2006;103:1446-1451.
32. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood. 2004;103:291-300.
33. Zupo S, Cutrona G, Mangiola M, Ferrarini M, Schattner E, Bernal A. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood. 2002;99: 2277-2278.
34. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98:3050-3057.
35. Underhill DM, Ozinsky A. Toll-like receptors:key mediators of microbe detection. Curr Opin Immunol. 2002;14:103-110.
36. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.